高盛发表研究报告指，科伦博泰-B(06990.HK) 去年下半年收入为11亿元人民币(下同)，高于该行及市场预期，主要由授权收入按年增长79%带动，但产品销售按半年跌25%，则逊预期，主要由于核心产品sac-TMT在2025年主要以自费形式销售，患者可及性受限，以及纳入国家医保目录后价格调整的渠道返点影响。管理层预期今年sac-TMT销售将倍增，目标成为医保目录内各个适应症的首选药物，占销售逾...
Source Link高盛发表研究报告指，科伦博泰-B(06990.HK) 去年下半年收入为11亿元人民币(下同)，高于该行及市场预期，主要由授权收入按年增长79%带动，但产品销售按半年跌25%，则逊预期，主要由于核心产品sac-TMT在2025年主要以自费形式销售，患者可及性受限，以及纳入国家医保目录后价格调整的渠道返点影响。管理层预期今年sac-TMT销售将倍增，目标成为医保目录内各个适应症的首选药物，占销售逾...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.